Why Meta Rejects Ayurvedic Ads — and How Compliant Brands Scale Anyway
Your ad was legal, your product is licensed, and the rejection is real anyway — because Meta's reviewer is a classifier, not a lawyer. The brands that scale in this category stopped arguing with the machine and built a system around it.
In short: Meta enforces its health policies by algorithm at a scale where false positives are the accepted cost, so Ayurvedic ads get rejected for legal phrasing — and repeated rejections quietly damage account standing and delivery. Compliant brands scale anyway with a six-part system: a pre-cleared claims library, review-proof creative angles, landing-page hygiene, resilient account architecture, channel diversification, and disciplined appeals. Educational only — not legal advice.
Educational content, not legal advice: advertising rules and platform policies change, and their application depends on your licence and product. Take specific decisions with qualified counsel.
Why does Meta keep rejecting ads that are perfectly legal?
Because the review you face first is not a human reading your ad against Indian law — it is a stack of classifiers scanning text, image, landing page and account history against Meta’s global health policies, tuned to err on the side of removal. Three policy families do most of the damage to Ayurvedic advertisers. Health and wellness restrictions flag benefit language, symptom references and anything resembling a treatment promise. The personal-attributes rule rejects copy that implies the viewer has a condition — “struggling with hair fall?” is a rejection template, regardless of the remedy’s legality. And before-after or sensational imagery trips visual classifiers even when the copy is clean. None of these machines knows what an ASU licence is; your legally compliant ad is being judged by a system built for a different problem at planetary scale. The tactical what-to-do-on-rejection-day playbook — rewrites, appeals, specificity — lives in our ad-rejection guide; this piece is about the system above it: why the wall exists, and how brands grow tall next to it.
As of 2026: Meta’s own transparency reporting has long stated that the overwhelming majority of policy enforcement happens through automated systems before any human review — and in India, ASCI’s annual complaints reports have repeatedly ranked healthcare, Ayush and wellness advertising among the most-violative sectors they process. Put together: the platform has every statistical reason to keep its health classifiers aggressive, and the false positives that catch compliant Ayurvedic brands are the accepted cost of that design.
What does a rejection actually cost you beyond the ad?
The rejected ad is the cheapest part. Ad accounts carry quality history, and a pattern of policy flags correlates with the things advertisers actually feel: more ads routed to slower review, campaigns restarting learning after edits, restricted features, and — at the bad end — disabled accounts that take your pixel history and custom audiences down with them. There is a compounding tax, too: teams that get burned start self-censoring into beige, claim-free creative that passes review and persuades nobody, which shows up as rising CPMs and falling conversion long before anyone connects it to the rejection spiral. Treating each rejection as an isolated annoyance is how brands walk into the compounding version.
How do compliant Ayurvedic brands scale anyway?
The scaled accounts we see share a six-part system rather than a clever trick:
- 1. A pre-cleared claims library. Every approved phrase, benefit frame and ingredient statement — vetted against your licence, the DMR Act schedule and ASCI’s code, with counsel where it matters — lives in one document creative teams draw from. Nobody writes claims at 11 p.m. in Ads Manager.
- 2. Review-proof creative angles. Whole persuasion territories carry near-zero rejection risk: ritual and routine framing, ingredient provenance and sourcing story, taste and format, heritage and process, lifestyle casting. The craft is making these sell — which is a creative-volume problem, not a claims problem.
- 3. Landing-page hygiene. Meta reads the destination too: a clean ad pointing at a page shouting cure-adjacent testimonials still gets flagged. The claims library governs the PDP, the reviews you surface and the pop-ups, not just the ads.
- 4. Resilient account architecture. Verified business assets, clean payment history, conservative edit cadence on flagged campaigns, and separation between experimental and proven structures — so one bad review cycle cannot take the whole machine down.
- 5. Channel diversification on purpose. Google Search meets declared intent where health policies bite differently; quick commerce sells where no claim is needed at all; creator content carries lived-experience persuasion under ASCI disclosure rules — the blend maths from influencer vs performance applies squarely here.
- 6. Appeals discipline. Appeal genuine false positives calmly and once; rewrite everything else. Arguing with the classifier is not a growth channel.
Which ad angles survive review and still sell?
The pattern behind every durable winner in this category: move the persuasion from the outcome to the evidence. Sourcing films — the farm, the classical process, the testing lab — build the trust a claim would have shortcut. Ritual demonstrations put the product inside a daily routine and let the viewer infer the benefit the copy never states. Ingredient-education carousels make the customer feel smart rather than sold to. Founder and expert voices carry authority within the boundaries we detail in doctor-led content without medical claims. And honest-gradualism copy — “built for the long habit, not the overnight fix” — converts the category’s legal constraint into a positioning asset. Across our portfolio (160+ brands, 3.8× average ROAS over six years), the claim-free angles do not merely pass review; at creative-testing volume they routinely out-convert the borderline copy they replaced, because this buyer’s scepticism responds to proof, not promises.
When is the problem your product page, not your ad?
A specific, common trap: media teams sand the ads down to compliance while the site underneath still reads like a miracle catalogue — so approval rates recover and conversion collapses, or worse, the landing-page classifier keeps flagging the account and everyone blames the creative. Run the claims library over every PDP, review widget and WhatsApp broadcast the way we did in the Butterfly Ayurveda engagement, where clearing the site’s conversion and technical roadblocks — not louder ads — was what uncapped demand. If your rejection rate is fine and growth still is not, the constraint has usually moved down-funnel. The wider category picture sits in the AYUSH playbook and on our nutrition and wellness page.
Frequently asked questions
Why does Meta reject Ayurvedic ads that don't break Indian law?
Because Meta's first reviewer is an automated policy system, not a lawyer reading Indian regulations. Classifiers scan copy, imagery and landing pages against global health policies — benefit language, implied personal attributes like 'struggling with hair fall?', and before-after visuals all trigger flags regardless of the product's legal status. False positives on compliant ads are the accepted cost of enforcing at that scale.
Do repeated ad rejections hurt a Meta ad account?
Yes, and this is the expensive part. Accounts carry quality history, and repeated policy flags correlate with slower reviews, learning-phase resets, feature restrictions and ultimately account disablement — which takes pixel history and audiences with it. A rejection pattern is an account-level risk to be managed systematically, not a series of one-off annoyances to resubmit past.
How can an Ayurvedic brand scale on Meta without making health claims?
By moving persuasion from outcome to evidence: sourcing and process films, ritual and routine demonstrations, ingredient education, founder and practitioner authority, and honest time-to-effect framing. Run at proper creative-testing volume, these claim-free angles routinely out-convert borderline copy in this category, because the Ayurvedic buyer's scepticism responds to proof rather than promises.
Should you appeal a rejected Ayurvedic ad or just rewrite it?
Appeal once, calmly, when the ad is a genuine false positive against Meta's written policy — clean copy, clean imagery, clean landing page. Rewrite everything else, drawing from a pre-cleared claims library instead of improvising. Serial appeals on borderline ads add flags to an account that is already being watched, which costs more than any single ad was worth.
Is this article legal advice for AYUSH advertisers?
No. It is educational marketing commentary. Advertising law, licence conditions and platform policies change and apply differently to each product and claim — decisions about what your brand may say should be made with qualified legal counsel and your regulatory documentation.
Scale the account without fighting the machine
Book a free Growth Audit and we will review your rejection history, claims exposure and creative system — and show you where the compliant scale is hiding. Best fit: brands spending ₹3 lakh+ a month on ads.
Book a Growth Audit →